Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations
Despite the limited number of cases, our results support the use of CFTR modulators in patients with rare CFTR variants that are not currently approved for ETI in Europe.
Authors
- Francesco Longo (ORCID: https://orcid.org/0000-0002-7605-2953)
- Susanna Esposito (ORCID: https://orcid.org/0000-0003-4103-2837)
- Paola Melotti
- Emanuela Pesce (ORCID: https://orcid.org/0000-0002-9070-4479)
- Michela Deolmi
- Giovanna Pisi (ORCID: https://orcid.org/0000-0002-6673-0749)
- Valentina Fainardi (ORCID: https://orcid.org/0000-0003-4601-7484)
- Karina Kleinfelder
- Claudio Sorio
- Federico Cresta
Institutions
- University of Verona (IT)
- University of Parma (IT)
- Istituto Giannina Gaslini (IT)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Pediatric Pulmonology
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1002/ppul.27211
- Citations
- 7
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 2.93